An inferential study of the phenotype for the chromosome 15q24 microdeletion syndrome: a bootstrap analysis

Antonio Palazón-Bru, Dolores Ramírez-Prado, Ernesto Cortés, María S Aguilar-Segura, Vicente F Gil-Guillén

In January 2012 a review of the cases of chromosome 15q24 microdeletion syndrome was published. However this study did not include inferential statistics. The aims of the present study were to update the literature search and calculate confidence intervals for the prevalence of each phenotype using bootstrap methodology. Published case reports of patients with the syndrome that included detailed information about breakpoints and phenotype were sought and 36 were included. Deletions in megabase (Mb) pairs were determined to calculate the size of the interstitial deletion of the phenotypes studied in 2012. To determine confidence intervals for the prevalence of the phenotype and the interstitial loss, we used bootstrap methodology. Using the bootstrap percentiles method, we found wide variability in the prevalence of the different phenotypes (3-100%). The mean interstitial deletion size was 2.72 Mb (95% CI: 2.35-3.10 Mb). In comparison with our work, which expanded the literature search by 45 months, there were differences in the prevalence of 17% of the phenotypes, indicating that more studies are needed to analyze this rare disease.

1 Authors: Antonio Palazón-Bru^{1,2}, Dolores Ramírez-Prado^{3,4}, Ernesto Cortés⁴, María Soledad
2 Aguilar-Segura⁴, Vicente Francisco Gil-Guillén^{1,2}.

3 Institutions:

4 1: Clinical Medicine Department, Miguel Hernández University, San Juan de Alicante, Alicante,
5 Spain.

6 2: Research Unit, Elda Hospital, Elda, Alicante, Spain.

7 3: Clinical Analysis Department, Elda Hospital, Elda, Alicante, Spain.

8 4: Pharmacology, Pediatrics and Organic Chemistry Department, Miguel Hernández University,
9 San Juan de Alicante, Alicante, Spain.

10

11 Corresponding author: Prof. Antonio Palazón-Bru, PhD, Departament of Clinical Medicine,
12 Miguel Hernández University, Carretera de Valencia-Alicante S/N, San Juan de Alicante 03550,
13 Spain. Phone: +34 965919449. Fax: +34 965919450. E-mail: antonio.pb23@gmail.com

14

INTRODUCTION

Chromosome 15q24 microdeletion syndrome is a rare disease that was first analyzed by Sharp et al. in 2007, characterizing the phenotype and genotype of four patients with this syndrome (Sharp et al., 2007). Since this publication, further papers have contributed new cases, providing descriptive comparisons of the phenotype and genotype between the new case and those already described (Klopocki et al., 2008; Marshall et al., 2008; Andrieux et al., 2009; El-Hattab et al., 2009; Masurel-Paulet et al., 2009; Van Esch et al., 2009; El-Hattab et al., 2010; McInnes et al., 2010; Ng et al., 2011; Brun et al., 2012; Mefford et al., 2012; Narumi et al., 2012; Samuelsson et al., 2015). Five breakpoints (low-copy repeat [LCR] clusters) have been identified where the majority of the microdeletions have occurred: LCR15q24A, LCR15q24B, LCR15q24C, LCR15q24D, and LCR15q24E (Magoulas & El-Hattab, 2012).

As a result of these reports, in January 2012 Magoulas and El-Hattab conducted a comprehensive review of the cases reported up to that time (Magoulas & El-Hattab, 2012). In this review they descriptively analyzed the phenotypes of the patients with the syndrome, both in detail and in large groups. However, as this work did not include inferential statistics calculating the proportion of children with the different phenotypes with their confidence intervals (CI), we conducted a study to update the literature search and to determine the corresponding ranges for each phenotype using bootstrap methodology. The results provide a better understanding of this rare condition.

MATERIALS AND METHODS

Study population

The population included all individuals with chromosome 15q24 microdeletion syndrome.

Study design and participants

This pooled analysis study examined *MEDLINE* and *Google Scholar* databases for reported cases of patients with the syndrome, using the keywords *15q24*, *deletion* and *microdeletion*. The references in all the cases obtained were reviewed to detect possible studies not found in the databases analyzed, in order to collect all the papers that had been used as references to cases of the syndrome. This search was updated on September 29, 2015.

Starting with the second published case report, the authors compared the characteristics of their patients with the published cases (Klopocki et al., 2008; Marshall et al., 2008; Andrieux et al., 2009; El-Hattab et al., 2009; Masurel-Paulet et al., 2009; Van Esch et al., 2009; El-Hattab et al., 2010; McInnes et al., 2010; Ng et al., 2011; Brun et al., 2012; Mefford et al., 2012; Narumi et al., 2012; Samuelsson et al., 2015). We analyzed all the references in these case reports in order to obtain the maximum sample size.

Variables and measurements

First, we determined which children had each of these phenotypes: male gender, developmental delay, low birth weight/intrauterine growth restriction, short stature, obesity, microcephaly, feeding difficulties, long face, facial asymmetry, high anterior hairline, epicanthal folds, hypertelorism, downslanting palpebral fissures, sparse and broad medial eyebrows, strabismus, nystagmus, broad nasal base, depressed nasal bridge, high nasal bridge, ear abnormalities, palate abnormalities, long smooth philtrum, full lower lip, small mouth, hypospadias, microphallus, cryptorchidism, thumb abnormalities, brachydactyly/short digits, clynodactyly, toe

abnormalities, joint laxity, scoliosis/kyphosis, hypotonia, behavior problems, magnetic resonance imaging (MRI) abnormalities, recurrent infections, hernias, congenital heart disease, hearing loss, diaphragmatic hernia, intestinal atresia, imperforate anus, coloboma, dental problems and myelomeningocele. The phenotypes used followed the previous review (El-Hattab et al., 2010). The deleted megabase (Mb) pairs in each patient were determined to calculate the size of the interstitial deletion of chromosome 15q24 (in Mb). Finally, we also analyzed the five breakpoints (Magoulas & El-Hattab, 2012).

The source of information was the selected papers, i.e., those containing complete information on phenotype and genotype (Mb).

Sample size

The sample size was 40 patients, 4 of whom were excluded due to lack of the information required for this study (Mb and phenotype). The final sample consisted of 36 patients.

Statistical methods

The phenotype was described using absolute frequencies. One thousand bootstrap samples were obtained to determine the relative distribution frequency for the phenotypes and the mean loss size of the interstitial deletion of chromosome 15q24 (in Mb). Using these samples, we calculated a point estimate (median) and a CI (percentiles method) for these parameters (proportions and means). Thus we obtained a measurement of the uncertainty for the relative frequencies and for the mean, since with a small sample size we could not perform an asymptotic approximation of the normal distribution ($n=36$). This bootstrap methodology was based on taking 1,000 simple random samples with replacement of the original sample. For each sample we calculated the statistic of interest (in our case proportions/means). At the end of the process

we obtained 1,000 values for the statistic. In other words, we had a distribution of the statistic from which we could then calculate its estimation (median) with its CI (P2.5 – P97.5). This method is very useful for obtaining the CI for statistics which are difficult to calculate (no closed form or with hypotheses which are not present). The computational cost is the only aspect of this method that is inadequate, but as our sample was small, this was not a problem. This methodology has already been applied with other rare diseases (Chiano & Yates, 1994). All analyses were performed with a significance level of 5%. The statistical software used was IBM SPSS Statistics 19.

RESULTS

Table 1 shows the descriptive and analytical features of all the patients found in the literature search. We highlight the wide variability in the prevalence of the different phenotypes (3-100%). The phenotype with the lowest prevalence was myelomeningocele, which was only present in one case, whereas developmental delay was common in all cases (n=36). The mean interstitial deletion loss was 2.72 Mb (95% CI: 2.35-3.10 Mb). Regarding the five breakpoints, we obtained the following results (patients who presented the deletion at the breakpoint): A) 19 (0.53, 95% CI: 0.36-0.69); B) 30 (0.83, 95% CI: 0.69-0.94); C) 25 (0.69, 95% CI: 0.56-0.86); D) 11 (0.31, 95% CI: 0.17-0.47); and E) 9 (0.25, 95% CI: 0.11-0.39).

DISCUSSION

Summary

This study updates the descriptive analysis of the different phenotypes conducted in 2012

(Magoulas & El-Hattab, 2012), and provides inferential information on a range of values within which the true proportion of each phenotype in the study population can likely be found (95% CI).

Strengths and limitations of the study

The main strength of this study is that, for the first time, a measurement of the uncertainty of the proportion of each phenotype in the population has been obtained using inferential statistics (bootstrap samples). In addition, the descriptive data provided by Magoulas and El-Hattab (Magoulas & El-Hattab, 2012) have also been updated.

Concerning the limitations of this study, we have to assume a possible selection bias, since it is possible that not all incident cases of this syndrome have been published or that in our search strategy we may not have found all recently published cases, as we did not include the DECIPHER and ECARUCA databases. To minimize this bias as much as possible, we rigorously reviewed all the references for each of the articles. In terms of reporting bias, it is possible that not all the features have been specified in each of the cases. For example, MRI abnormalities: not all reported patients would have had an MRI scan done. In those cases the statistics for MRI abnormalities would be difficult to derive. Regarding obesity, the other authors used the Z-score for its assessment. In other words, the researchers took into account the age and gender of the patients. Other features are largely descriptive (thumb abnormalities, hypertelorism and brachydatyly) and thus subject to single clinical observer bias. Finally, the information was obtained through the publications instead of by contacting the authors. For obvious reasons, this information bias cannot be minimized. If we were analyzing associations between phenotypes and genotypes, this bias could give us incorrect information about the associations. However, we

only obtained descriptive statistics with their confidence interval using the original sample through bootstrap methodology.

Comparison with the existing literature

To compare our results with those found by the 2012 study (Magoulas & El-Hattab, 2012), we determined whether the point estimate given by the previous study was within the CI we constructed for each phenotype. Such that if the estimate of the other study fell within that range, we had no evidence indicating that the proportion was different from that of our study (Magoulas & El-Hattab, 2012). However, if this estimate fell outside our CI, there was a difference compared with our study.

Overall we found agreement between both studies, as the previous estimate in nearly 83% of the phenotypes (38/46) was within our CI. The eight phenotypes that showed discrepancies with the previous study (Magoulas & El-Hattab, 2012) were facial asymmetry, high anterior hairline, hypertelorism, broad nasal base, hypospadias, microphallus, thumb abnormalities, and clynodactyly, all of which were approximately twice as prevalent in the earlier study (Magoulas & El-Hattab, 2012) than in our study. To assess the reasons for these discrepancies we need further studies on this syndrome, because they cannot be determined using our study design.

Implications for research and/or practice

The comparative analysis between our results and those of the review published in 2012 (Magoulas & El-Hattab, 2012) revealed differences in 17% of the phenotypes. Given that the previous article was accepted for publication in January 2012 (Magoulas & El-Hattab, 2012), and that our work expanded the literature analysis by approximately 45 months, it appears that the prevalence of the phenotypes in these patients is not fully known, which suggests the need

for future studies in this rare syndrome. When there are more published cases of this rare syndrome, it would be very interesting to determine associations between the phenotypes and the size of the deletion. These associations were not studied in our paper because with 36 patients we would not have been able to obtain valid conclusions. Finally, it would be interesting to measure some phenotypes with facial recognition software (facial asymmetry, high anterior hairline, hypertelorism and broad nasal base).

Once we have this new knowledge, we can devise strategies to improve our decisions regarding these patients. For instance, we could attempt to determine where the breakpoint is using only the information about the phenotype.

CONCLUSIONS

The prevalence of the different phenotypes in patients with chromosome 15q24 microdeletion syndrome, published in early 2012 (Magoulas & El-Hattab, 2012), has been updated. The CI were calculated based on bootstrap samples for these proportions, providing a measurement of the uncertainty in the study population. Furthermore, differences between our study and the 2012 study were found in approximately one in six phenotypes, which suggests more studies are needed to analyze the characteristics of this rare syndrome.

ACKNOWLEDGEMENTS

We thank Maria Repice and Ian Johnstone for their help in preparing the English version of this work.

169 REFERENCES

170 Andrieux J, Dubourg C, Rio M, Attie-Bitach T, Delaby E, Mathieu M, Journal H, Copin H,
 171 Blondeel E, Doco-Fenzy M, Landais E, Delobel B, Odent S, Manouvrier-Hanu S, Holder-
 172 Espinasse M. 2009. Genotype-phenotype correlation in four 15q24 deleted patients identified by
 173 array-CGH. *American Journal of Medical Genetics Part A* 149A:2813-2819.

174

175 Brun A, Cailley D, Toutain J, Bouron J, Arveiler B, Lacombe D, Goizet C, Rooryck C. 2012. 1.5
 176 Mb microdeletion in 15q24 in a patient with mild OAVS phenotype. *European Journal of*
 177 *Medical Genetics* 55:135-139.

178

179 Chiano MN, Yates JR. 1994. Bootstrapping in human genetic linkage. *Annals of Human*
 180 *Genetics* 58(Pt 2):129-143.

181

182 El-Hattab AW, Smolarek TA, Walker ME, Schorry EK, Immken LL, Patel G, Abbott MA,
 183 Lanpher BC, Ou Z, Kang SH, Patel A, Scaglia F, Lupski JR, Cheung SW, Stankiewicz P. 2009.
 184 Redefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint
 185 mapping. *Human Genetics* 126:589-602.

186

187 El-Hattab AW, Zhang F, Maxim R, Christensen KM, Ward JC, Hines-Dowell S, Scaglia F,
188 Lupski JR, Cheung SW. 2010. Deletion and duplication of 15q24: molecular mechanisms and
189 potential modification by additional copy number variants. *Genetics in Medicine* 12:573-586.

190

191 Hanley JA, McNeil BJ. 1982. The meaning and use of the area under a receiver operating
192 characteristic (ROC) curve. *Radiology* 143:29-36.

193

194 Hanley JA. 1989. Receiver operating characteristic (ROC) methodology: the state of the art.
195 *Critical Reviews in Diagnostic Imaging* 29:307-335. Review.

196

197 Klopocki E, Graul-Neumann LM, Grieben U, Tönnies H, Ropers HH, Horn D, Mundlos S,
198 Ullmann R. 2008. A further case of the recurrent 15q24 microdeletion syndrome, detected by
199 array CGH. *European Journal of Pediatrics* 167:903-908.

200

201 L Ng IS, Chin WH, P Lim EC, Tan EC. 2011. An additional case of the recurrent 15q24.1
202 microdeletion syndrome and review of the literature. *Twin Research and Human Genetics*
203 14:333-339.

204

205 Magoulas PL, El-Hattab AW. 2012. Chromosome 15q24 microdeletion syndrome. *Orphanet*
206 *Journal of Rare Diseases* 7:2. Review.

207

208 Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D,
209 Ren Y, Thiruvahindrapduram B, Fiebig A, Schreiber S, Friedman J, Ketelaars CE, Vos YJ,
210 Ficicioglu C, Kirkpatrick S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat
211 D, Weksberg R, Thompson A, Vardy C, Crosbie V, Luscombe S, Baatjes R, Zwaigenbaum L,
212 Roberts W, Fernandez B, Szatmari P, Scherer SW. 2008. Structural variation of chromosomes in
213 autism spectrum disorder. *American Journal of Human Genetics* 82:477-488.

214

215 Martínez-Orozco MJ, Perseguer-Torregrosa Z, Gil-Guillén VF, Palazón-Bru A, Orozco-Beltran
216 D, Carratalá-Munuera C. 2015. Suitability of antiplatelet therapy in hypertensive patients.
217 *Journal of Human Hypertension* 29:40-45.

218

219 Masurel-Paulet A, Callier P, Thauvin-Robinet C, Chouchane M, Mejean N, Marle N, Mosca AL,
220 Ben Salem D, Giroud M, Guibaud L, Huet F, Mugneret F, Faivre L. 2009. Multiple cysts of the
221 corpus callosum and psychomotor delay in a patient with a 3.1 Mb 15q24.1q24.2 interstitial
222 deletion identified by array-CGH. *American Journal of Medical Genetics Part A* 149A:1504-
223 1510.

224

225 McInnes LA, Nakamine A, Pilorge M, Brandt T, Jiménez González P, Fallas M, Manghi ER,
226 Edelmann L, Glessner J, Hakonarson H, Betancur C, Buxbaum JD. 2010. A large-scale survey of

the novel 15q24 microdeletion syndrome in autism spectrum disorders identifies an atypical deletion that narrows the critical region. *Molecular Autism* 1:5.

Mefford HC, Rosenfeld JA, Shur N, Slavotinek AM, Cox VA, Hennekam RC, Firth HV, Willatt L, Wheeler P, Morrow EM, Cook J, Sullivan R, Oh A, McDonald MT, Zonana J, Keller K, Hannibal MC, Ball S, Kussmann J, Gorski J, Zelewski S, Banks V, Smith W, Smith R, Paull L, Rosenbaum KN, Amor DJ, Silva J, Lamb A, Eichler EE. 2012. Further clinical and molecular delineation of the 15q24 microdeletion syndrome. *Journal of Medical Genetics* 49:110-118.

Narumi Y, Shiohara M, Wakui K, Hama A, Kojima S, Yoshikawa K, Amano Y, Kosho T, Fukushima Y. 2012. Myelodysplastic syndrome in a child with 15q24 deletion syndrome. *American Journal of Medical Genetics Part A* 158A:412-416.

Ramírez-Prado D, Palazón-Bru A, Folgado-de-la Rosa DM, Carbonell-Torregrosa MA, Martínez-Díaz AM, Gil-Guillén VF. 2015. Predictive models for all-cause and cardiovascular mortality in type 2 diabetic inpatients. A cohort study. *International Journal of Clinical Practice* 69:474-484.

Samuelsson L, Zagoras T, Hafström M. Inherited 15q24 microdeletion syndrome in twins and their father with phenotypic variability. 2015. *European Journal of Medical Genetics* 58:111-115.

248

249 Sharp AJ, Selzer RR, Veltman JA, Gimelli S, Gimelli G, Striano P, Coppola A, Regan R, Price
 250 SM, Knoers NV, Eis PS, Brunner HG, Hennekam RC, Knight SJ, de Vries BB, Zuffardi O,
 251 Eichler EE. 2007. Characterization of a recurrent 15q24 microdeletion syndrome. *Human*
 252 *Molecular Genetics* 16:567-572.

253

254 Van Esch H, Backx L, Pijkels E, Fryns JP. 2009. Congenital diaphragmatic hernia is part of the
 255 new 15q24 microdeletion syndrome. *European Journal of Medical Genetics* 52:153-156.

Table 1(on next page)

Descriptive and analytical features of the phenotypes of the patients with chromosome 15q24 microdeletion syndrome.

CI, confidence interval; IUGR, intrauterine growth restriction; MRI, magnetic resonance imaging; *, only for male gender.

Phenotype	Total n=36	Proportion (95% CI)	Phenotype	Total n=36	Proportion (95% CI)
Male gender	27	0.75 (0.61-0.89)	Small mouth	9	0.25 (0.11-0.39)
Developmental delay	36	1 (1-1)	Hypospadias	9	0.25 (0.11-0.39)
Low birth weight/IUGR	14	0.39 (0.22-0.56)	Microphallus*	5	0.19 (0.04-0.36)
Short stature	11	0.31 (0.17-0.47)	Cryptorchidism	4	0.11 (0.03-0.22)
Obesity	8	0.22 (0.08-0.36)	Thumb abnormalities	8	0.22 (0.11-0.36)
Microcephaly	8	0.22 (0.08-0.36)	Brachydactyly/short digits	12	0.33 (0.19-0.50)
Feeding difficulties	7	0.19 (0.08-0.33)	Clynodactyly	3	0.08 (0.00-0.19)
Long face	9	0.25 (0.11-0.42)	Toe abnormalities	10	0.28 (0.14-0.44)
Facial asymmetry	5	0.14 (0.03-0.25)	Joint laxity	14	0.39 (0.22-0.56)
High anterior hairline	11	0.31 (0.17-0.47)	Scoliosis/Kyphosis	8	0.22 (0.08-0.36)
Epicanthal folds	17	0.47 (0.31-0.64)	Hypotonia	18	0.50 (0.33-0.64)
Hypertelorism	8	0.22 (0.08-0.36)	Behavior problems	16	0.44 (0.28-0.58)
Downslanting palpebral fissures	15	0.42 (0.25-0.58)	MRI abnormalities	13	0.36 (0.19-0.53)
Sparse broad medial eyebrows	15	0.42 (0.25-0.58)	Recurrent infections	11	0.31 (0.17-0.44)
Strabismus	10	0.28 (0.14-0.44)	Hernias	5	0.14 (0.03-0.28)
Nystagmus	3	0.08 (0.00-0.19)	Congenital heart disease	8	0.22 (0.11-0.36)
Broad nasal base	5	0.14 (0.03-0.25)	Hearing loss	10	0.28 (0.14-0.42)
Depressed nasal bridge	6	0.17 (0.06-0.31)	Diaphragmatic hernia	2	0.06 (0.00-0.14)
High nasal bridge	2	0.06 (0.00-0.14)	Intestinal atresia	2	0.06 (0.00-0.14)
Ear abnormalities	21	0.58 (0.42-0.75)	Imperforate anus	2	0.06 (0.00-0.14)
Palate abnormalities	8	0.22 (0.08-0.36)	Coloboma	2	0.06 (0.00-0.14)
Long smooth philtrum	15	0.42 (0.25-0.58)	Dental problems	3	0.08 (0.00-0.19)
Full lower lip	9	0.25 (0.14-0.42)	Myelomeningocele	1	0.03 (0.00-0.08)